Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-25-003497
Filing Date
2025-08-12
Accepted
2025-08-12 09:01:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10662
  Complete submission text file 0000902664-25-003497.txt   12321
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Subject) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)